logo
Plus   Neg
Share
Email

Acorda Reports Top Line Results Of Study Exploring 5 Mg Dose Of Dalfampridine-ER

Acorda Therapeutics, Inc. (ACOR) announced top line results from a post-marketing commitment study assessing a 5mg dose of dalfampridine-ER to improve walking in people with multiple sclerosis, or MS. The study failed to confirm efficacy of the 5mg dose.

According to the company, the study randomized 430 participants across three treatment arms - placebo, 5 mg or the currently marketed dose of 10 mg of dalfampridine-ER, twice daily. Baseline characteristics were measured at a single visit after randomization, following a qualifying screening visit. Study drug was then given for 4 weeks. Participants returned after 2 weeks on study drug for interim measurements (Visit 2) and again at 4 weeks (Visit 3).

Acorda noted that the primary outcome was the change in walking speed (feet/second) on the Timed 25-Foot Walk test at Visit 3, measured at the time of peak plasma drug concentration, versus baseline. Improvements in the primary outcome for the 5 mg dose and the 10 mg dose at Visit 3 were not statistically significant compared to placebo, the company added.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Down the line, GE has transformed from a too-big-to-fail conglomerate to a too-big-for-success albatross. The company has admitted to being too-much focused on EPS and operating profit, and not paying enough attention to cash. However, GE is certainly learning lessons from its past and refocusing its strategies to stage a comeback to its Camelot days, the key catalysts being... Industrial conglomerate General Electric Co., one of the original components of the Dow Jones Industrial Average, has been replaced by Walgreens Boots Alliance Inc. in the blue-chip index. The change comes into effect prior to the open of trading on Tuesday, June 26. The 122-year-old Dow Jones Industrial Average, or simply the Dow, is a stock market index with 30 component companies. A $716 billion defense policy bill easily cleared the Senate on Monday, although the legislation must still be reconciled with the version previously approved by the House. The Senate voted 85 to 10 in favor of the National Defense Authorization Act, which authorizes U.S. military spending for fiscal 2019.
Follow RTT